A study examining the influence of immune senescence on anti-PD-(L)1 therapy in patients with advanced NSCLC found that CD28-CD57+KLRG1+CD8+ T cells (Terma-like CD8+ T cells) were associated with a lack of benefit from PD-(L)1 immunotherapy (20). Here, CD8A is linked to non-small cell lung carcinoma.